Viridian Therapeutics, Inc.
22.37USD
-0.4500 (-1.97%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on VRDN.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 71 | 0 | 0 | 0 | 0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -126 | -116 | -123 | -40 | -107 | -94 | -87 | -83 |
| Net Income | -127 | -105 | -120 | -35 | -101 | -87 | -80 | -77 |
| EPS (Diluted) | — | — | — | — | — | — | — | -$1.15 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)